Swainsonine protects both murine and human haematopoietic systems from chemotherapeutic toxicity

British Journal of Cancer

Volumn 80, Issue 1-2, 1999, Pages 87-95

  Klein, J L D ^a,e   Roberts, J D ^a   George, M D ^a   Kurtzberg, J ^b   Breton, P ^c   Chermann, J C ^d   Olden, K ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b DUKE UNIVERSITY HOSPITAL   (United States)

^c UPSA Laboratories   (France)

^d INSERM   (France)

^e GLAXOSMITHKLINE   (United States)

Author keywords

AZT; Bone marrow; Cancer; Cyclophosphamide; Swainsonine

Indexed keywords

ANTINEOPLASTIC ALKALOID; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; SWAINSONINE; ZIDOVUDINE;

ANIMAL CELL; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; COLONY FORMING CELL; ERYTHROID CELL; FEMALE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CYCLOPHOSPHAMIDE; DRUG INTERACTIONS; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; SWAINSONINE; TUMOR CELLS, CULTURED; ZIDOVUDINE;

EID: 0032949437     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690326     Document Type: Article

References (36)

1. Abraham NG, Chertkov JL, Staudinger R, Jiang S, Lutton JD, Argani I, Levere RD and Kappas A (1993) Long-term bone marrow stromal and hemopoietic toxicity to AZT: protective role of heme and IL-1. Exp Hematol 21: 263-268
2. Aidoudi S, Guigon M, Lebeurier I, Caen JP and Han ZC (1996) In vivo effect of platelet factor 4 (PF4) and tetrapeptide AcSDKP on haemopoiesis of mice treated with 5-fluorouracil. Br J Haemotol 94: 443-448
3. Aviles A, Alatriste S, Talavera A, Delgado S and Rosas A (1995) Alternating combination chemotherapy and interferon improves survival in poor prognosis multiple myeloma. Clin Oncol R Coll Radiol 7: 97-101
4. Calenda V, Sebahoun G and Chermann JC (1992a) Modulation of normal human erythropoietic progenitor cells in long-term liquid cultures after HIV-1 infection. AIDS Res Hum Retroviruses 8: 61-67
5. Calenda V, Tamalet C and Chermann JC (1992b) Transient stimulation of granulopoiesis and drastic inhibition of erythropoiesis in HIV-2-infected long-term liquid bone marrow cultures. J Acquired Immune Def Syndr 5: 1148-1157
6. Calenda V, Silvy F and Chermann JC (1993) Effects of thymus humoral factor gamma-2 on lymphohaematopoietic progenitor cells: an in vitro study. Res Immunol 144: 395-406
7. Cronkite EP and Bullis J (1990) In vivo toxicity of 3′-azido 3′-deoxythymidine (AZT) on CBA/Ca mice. Int J Cell Cloning 8: 332-345
8. Davey RT, Davey VJ, Metcalf JA, Zurlo JJ, Kovacs JA, Falloon J, Polis MA, Zunich KM, Masur H and Lane HC (1991) A phase I/II trial of zidovudine, interferon-α, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. J Infect Dis 164: 43-52
9. Donadieu J, Boutard P, Bernatowska E, Tchernia G, Couillaud G, Philippe N and Le Gall E (1997) A European phase II study of recombinant human granulocyte colony-stimulated factor (lenograstim) in the treatment of severe chronic neutropenia in children. Eur J Ped 156: 693-700
10. Dorr RT and Fritz WL (1980) Cancer Chemotherapy Handbook. Elsevier North Holland, Inc: New York
11. Elbein AD. Solf R, Dorling P and Vosbeck K (1981) Swainsonine: an inhibitor of glycoprotein processing. Proc Natl Acad Sci USA 78: 285-295
12. Elion GB, Singer S and Hitchings GH (1954) Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolities. J Biol Chem 208: 477-488
13. Fischl M, Galpin JE, Levine JD, Groopman JE, Henry DH, Kennedy P, Miles S, Robbins W, Starrett B, Zaluskj R, Abels R, Tsai HC and Rudnick SA (1990) Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 322: 1488-1493
14. Gisselbrecht C, Haioun C, Lepage E, Bastion Y, Tilly H, Bosly A, Dupriez B, Marit G, Herbrecht R, Deconinck E, Marolleau J-P, Yver A, Dabouz-Harrouche F, Coiffier B and Reyes F (1997) Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration. Leuk Lymph 25: 289-300
15. Goss PE, Baptiste J, Fernandes B, Baker M and Dennis JW (1994) A study of swainsonine in patients with advanced malignancies. Cancer Res 54: 1450-1457
16. Hoagland CH (1992) Hematologic complications of cancer chemotherapy. In The Chemotherapy Source Book, Perry MC (ed), pp. 498-507. Williams & Wilkins: Baltimore
17. Humphries MJ, Matsumoto K, White SL and Olden K (1986) Oligosaccharide modification by swainsonine treatment inhibits pulmonary colonization of B16-F10 murine melanoma cells. Proc Natl Acad Sci USA 83: 1752-1756
18. Hunter MG, Bawden L, Brotherton D, Graig S, Cribbes S, Czaplewski LG, Dexter TM, Drummond AH, Gearing AH, Heyworth CM, Lord BI, McCourt M, Varley PG, Wood LM, Edwards RM and Lewis PJ (1995) BB-10010: an active variant of human macrophage inflammatory protein-1α with improved pharmaceutical properties. Blood 86: 4400-4408
19. Laporte JP, Fouillard L and Dovay L (1991) GM-CSF instead of autologous bone marrow transplantation after BEAM regimen. Lancet 338: 601-602
20. Lord BI, Dexter TM, Clements JM, Humter MA and Gearing AJH (1992) Macrophage-inflammatory protein protects multipotent hematopoietic cells from the cytotoxic effects of hydroxyurea in vivo. Blood 79: 2605-2609
21. McLeod GX and Hammer SM (1992) Zidovudine: five years later. Ann Int Med 117: 487-501
22. Miles SA (1992) Hematopoietic growth factors as adjunets to antiretroviral therapy. AIDS Res Hum Retroviruses 8: 1073-1080
23. Olden K, Breton P, Grzegorzewski K, Yasuda Y, Gause BL, Oredipe OA, Newton SA and White SL (1991) The potential importance of swainsonine in therapy for cancers and immunology. Pharmacol Ther 50: 285-290
24. Oredipe OA, White SL, Grzegorzewski K, Gause BL, Cha JK, Miles VA and Olden K (1991) Protective effects of swainsonine on murine survival and bone marrow proliferation during cytoloxic chemotherapy. J Natl Cancer Inst 83: 1149-1156
25. Perry MC (1992) The Chemotherapy Source Book. Williams & Wilkins: Baltimore
26. Pratt WB, Ruddon RW, Ensminger WD and Maybaum J (1994) The Anticancer Drugs. Oxford University Press: New York
27. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS, Jackson GG, Durack DT, Phil D and Nusinoff-Lehrman S (1987) The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS-related complex. N Engl J Med 317: 192-197
28. Shaunak S and Bartlett JA (1989) Zidovudine-induced neutropenia: are we too cautious? Lancet I: 91-92
29. Thompson MB, Dunnick JK, Sutphin ME, Giles HD, Irwin RD and Prejeon JD (1991) Hematologic toxicity of AZT and ddC administered as single agents and in combination to rats and mice. Fund App Toxicol 17: 159-176
30. Tulsiani DRP, Harris T and Touster O (1982) Swainsonine inhibits the biosynthesis of complex glycoproteins by inhibition of golgi mannosidase II. J Biol Chem 257: 7936-7939
31. Tulsiani DRP and Touster O (1983) Swainsonine causes the production of hybrid glycoproteins by human skin fibroblasts and rat liver Golgi preparations. J Biol Chem 258: 7578-7585
32. Vose JM and Armitage JO (1992) Bone marrow transplantation. In The Chemotherapy Source Book, Perry MC (ed), pp. 498-507. Williams & Wilkins: Baltimore
33. Walker R, Parker R, Kovacs JA, Masur H, Gralnick H, Lane HC and Fauci AS (1987) 3′-Azido-3′-deoxythymidine causes red cell aplasia and hypoplasia in AIDS patients with Kaposi's sarcoma. Clin Res 35: 435A
34. Watanabe T, Kelsey LS, Yan Y, Brown GS, Jackson JD, Ewel C and Talmadge JE (1996) In vivo haemoprotective activity of tetrapeptide AcSDKP combined with granulocyte-colony stimulating factor following sublethal irradiation. Br J Haematol 94: 619-627
35. Yarchoan R, Mitsuya H, Myers CE and Broder S (1989) Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 321: 726-773
36. Zaretsky MD (1995) AZT toxicity and AIDS prophylaxis: Is AZT beneficial for HIV+ asymptomatic persons with 500 or more T4 cells per cubic millimeter? Genetica 95: 91-101